Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal

Authors

  • Vasco Quaresma Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra. https://orcid.org/0000-0001-9225-1437
  • Lorenzo Marconi Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra; Faculty of Medicine. University of Coimbra. Coimbra.
  • Roberto Jarimba Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • João Lima Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra.
  • Arnaldo Figueiredo Urology Department. Centro Hospitalar e Universitário de Coimbra. Coimbra; Faculty of Medicine. University of Coimbra. Coimbra.

DOI:

https://doi.org/10.20344/amp.18837

Keywords:

Carcinoma, Transitional Cell, Immunotherapy, Urinary Bladder Neoplasms/drug therapy

Abstract

N/a.

Downloads

Download data is not yet available.

References

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: longterm results in 1,054 patients. J Clin Oncol. 2001;19:666-75. DOI: https://doi.org/10.1200/JCO.2001.19.3.666

Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66:4-34. DOI: https://doi.org/10.1016/j.urology.2005.07.062

Galsky MD, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W, et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 2011;12:211-4. DOI: https://doi.org/10.1016/S1470-2045(10)70275-8

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fonf L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015-26. DOI: https://doi.org/10.1056/NEJMoa1613683

Hoffman-Censits JH, Grivas P, Van Der Heijden MS, Van-Der-Heijden M, Dreicer R, Loriot Y, et al. IMvigor 210, a phase II trial of atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC). J Clin Oncol. 2016;34:355. DOI: https://doi.org/10.1200/jco.2016.34.2_suppl.355

Downloads

Published

2023-02-01

How to Cite

1.
Quaresma V, Marconi L, Jarimba R, Lima J, Figueiredo A. Immunotherapy in the Treatment of Metastatic Urothelial Carcinoma at a Tertiary Referral Center in Portugal. Acta Med Port [Internet]. 2023 Feb. 1 [cited 2024 Mar. 29];36(2):145-6. Available from: https://www.actamedicaportuguesa.com/revista/index.php/amp/article/view/18837

Issue

Section

Letters to the Editor